The yield curve is the only economic indicator pointing to a recession, according to Credit Suisse.Marketsread more
Makan Delrahim, the assistant attorney general for the antitrust division, said a large group of bipartisan state attorneys general have spoken to the Justice Department about...Technologyread more
Stocks slipped on Tuesday as investors digested a sharp rebound from a strong sell-off last week.US Marketsread more
These are the stocks posting the largest moves midday.Market Insiderread more
An under-the-radar hedge fund is ruling the industry with a nearly 30% return this year on its long positions, and it's more than doubling its bet on gold.Marketsread more
Under terms of the deal, Genomic Health stockholders will receive $27.50 in cash and $44.50 in Exact Sciences stock, for a total value of $72 per share.
Wisconsin-based Exact Sciences makes non-invasive fecal DNA screening test Cologuard to help diagnose colorectal cancer.
Genomic Health develops and commercializes genomic-based diagnostics tests using its Oncotype IQ platform for various cancers, including breast and prostate.
The deal, expected to close by end-2019, is estimated to yield about $25 million in cost synergies within the third year, the companies said in a statement.
Shares of California-based Genomic Health rose 10.7% to $76.01 in early trading, while Exact Sciences' shares fell 3.3% to $114